Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.

Acta neuropathologica communications - 8 Apr 2022

Dhar Swati, Gadd Samantha, Patel Priyam, Vaynshteyn Jake, Raju G Praveen, Hashizume Rintaro, Brat Daniel J, Becher Oren J

Abstract excerpt

Pediatric high-grade gliomas, specifically diffuse midline gliomas, account for only 20% of clinical cases but are 100% fatal. A majority of the DMG cases are characterized by the signature K27M mutation in histone H3. The H3K27M mutation opposes the function of enhancer of zeste homolog 2 (EZH2), the methyltransferase enzyme of the polycomb repressor complex 2. However, the role of EZH2 in DMG pathogenesis is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histones

Share to Mutation

Share to Proteasome Endopeptidase Complex

Source

Open in PubMed Open full text

Identifiers

PMID: 35395831
DOI: 10.1186/s40478-022-01336-5
PMCID: PMC8994223

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.PMID 35395831Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

EZHIP's role in diffuse midline glioma: echoes of oncohistones?Semantic proximity Read ↗

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesSemantic proximity Read ↗

Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor SurvivalSemantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

H3F3A K27M mutations drive a repressive transcriptome by modulating chromatin accessibility independent of H3K27me3 in Diffuse Midline Glioma.Semantic proximity Read ↗

EZH2 inhibition sensitizes IDH1R132H mutant gliomas to histone deacetylase inhibitorSemantic proximity Read ↗

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.Semantic proximity Read ↗

Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.Semantic proximity Read ↗

Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomasSemantic proximity Read ↗

Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.Semantic proximity Read ↗

Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.